350 related articles for article (PubMed ID: 30587849)
1. Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy.
Liu C; He H; Li X; Su MA; Cao Y
Br J Cancer; 2019 Feb; 120(3):346-355. PubMed ID: 30587849
[TBL] [Abstract][Full Text] [Related]
2. Predicting tumour response to anti-PD-1 immunotherapy with computational modelling.
Valentinuzzi D; Simončič U; Uršič K; Vrankar M; Turk M; Jeraj R
Phys Med Biol; 2019 Jan; 64(2):025017. PubMed ID: 30561383
[TBL] [Abstract][Full Text] [Related]
3. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
4. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
[No Abstract] [Full Text] [Related]
5. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
6. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
7. Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy.
Xu YP; Lv L; Liu Y; Smith MD; Li WC; Tan XM; Cheng M; Li Z; Bovino M; Aubé J; Xiong Y
J Clin Invest; 2019 Jul; 129(10):4316-4331. PubMed ID: 31310587
[TBL] [Abstract][Full Text] [Related]
8. [Current events in immunotherapy for upper aerodigestive tract cancer].
Outh-Gauer S; Le Tourneau C; Broudin C; Scotte F; Roussel H; Hans S; Mandavit M; Tartour E; Badoual C
Ann Pathol; 2017 Feb; 37(1):79-89. PubMed ID: 28111039
[TBL] [Abstract][Full Text] [Related]
9. Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype.
Marchand L; Thivolet A; Dalle S; Chikh K; Reffet S; Vouillarmet J; Fabien N; Cugnet-Anceau C; Thivolet C
Acta Diabetol; 2019 Apr; 56(4):441-448. PubMed ID: 30284618
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
Komatsubara KM; Carvajal RD
Curr Oncol Rep; 2017 Jul; 19(7):45. PubMed ID: 28508938
[TBL] [Abstract][Full Text] [Related]
11. Coronary Toxicities of Anti-PD-1 and Anti-PD-L1 Immunotherapies: a Case Report and Review of the Literature and International Registries.
Ferreira M; Pichon E; Carmier D; Bouquet E; Pageot C; Bejan-Angoulvant T; Campana M; Vermes E; Marchand-Adam S
Target Oncol; 2018 Aug; 13(4):509-515. PubMed ID: 30006825
[TBL] [Abstract][Full Text] [Related]
12. Combined SEP and anti-PD-L1 antibody produces a synergistic antitumor effect in B16-F10 melanoma-bearing mice.
Hu Z; Ye L; Xing Y; Hu J; Xi T
Sci Rep; 2018 Jan; 8(1):217. PubMed ID: 29317734
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
[TBL] [Abstract][Full Text] [Related]
14. Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy.
Fang XN; Fu LW
Recent Pat Anticancer Drug Discov; 2016; 11(2):141-51. PubMed ID: 26916881
[TBL] [Abstract][Full Text] [Related]
15. Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma.
Takeuchi Y; Tanemura A; Tada Y; Katayama I; Kumanogoh A; Nishikawa H
Int Immunol; 2018 Feb; 30(1):13-22. PubMed ID: 29294043
[TBL] [Abstract][Full Text] [Related]
16. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
[TBL] [Abstract][Full Text] [Related]
17. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
18. Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade.
Fang L; Ly D; Wang SS; Lee JB; Kang H; Xu H; Yao J; Tsao MS; Liu W; Zhang L
J Exp Clin Cancer Res; 2019 Mar; 38(1):123. PubMed ID: 30857561
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression.
Bernard-Tessier A; Baldini C; Martin P; Champiat S; Hollebecque A; Postel-Vinay S; Varga A; Bahleda R; Gazzah A; Michot JM; Ribrag V; Armand JP; Marabelle A; Soria JC; Massard C
Eur J Cancer; 2018 Sep; 101():160-164. PubMed ID: 30071444
[TBL] [Abstract][Full Text] [Related]
20. Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma.
Cerezo M; Guemiri R; Druillennec S; Girault I; Malka-Mahieu H; Shen S; Allard D; Martineau S; Welsch C; Agoussi S; Estrada C; Adam J; Libenciuc C; Routier E; Roy S; Désaubry L; Eggermont AM; Sonenberg N; Scoazec JY; Eychène A; Vagner S; Robert C
Nat Med; 2018 Dec; 24(12):1877-1886. PubMed ID: 30374200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
